CJC-1295 with DAC (CJC-1295 DAC)

Long-Acting Growth Hormone Releasing Hormone Analog · Extended Release

Overview

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

Continuous growth hormone release for 6-8 days per injection.

Significantly elevates IGF-1 levels for extended periods.

Weekly dosing ideal for simple administration.

Continuous GH elevation promotes lipolysis and fat metabolism.

Mechanism

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

Continuous growth hormone release for 6-8 days per injection.

Research areas

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.
Continuous growth hormone release for 6-8 days per injection.
Significantly elevates IGF-1 levels for extended periods.
Weekly dosing ideal for simple administration.
Continuous GH elevation promotes lipolysis and fat metabolism.
Sustained anabolic environment supports muscle protein synthesis.
Accelerated healing and recovery from exercise or injury.

Research notes

Water retention
Joint pain
Carpal tunnel symptoms
Severe joint pain or carpal tunnel syndrome
Excessive water retention affecting daily life
Numbness or tingling in extremities
Significant blood glucose dysregulation
Signs of acromegaly (jaw growth, hand/feet enlargement)
Persistent lethargy indicating adrenal effects
Diabetes history
Cancer history
Predisposed sleep apnea

Pharmacokinetics

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

References

FAQs

How much more expensive is CJC-1295 with DAC compared to without DAC?

CJC-1295 with DAC typically costs 2-3x more than the non-DAC version due to complex albumin-binding manufacturing. The higher cost reflects the DAC technology enabling weekly dosing versus daily injections required for the basic version, making weekly administration more convenient despite the price premium.

Is CJC-1295 with DAC safe to combine with testosterone therapy?

CJC-1295 with DAC can be used with testosterone but requires careful monitoring. Combining continuous GH elevation with exogenous testosterone increases risk of joint pain, water retention, and elevated IGF-1 beyond safe levels. Most protocols separate them or use lower doses of each when combined.

Why does some people report joint pain during CJC-1295 DAC use?

Joint pain and carpal tunnel symptoms occur due to sustained GH and IGF-1 elevation causing water retention in joints and connective tissues. Unlike pulsatile protocols where GH spikes then drops, the 6-8 day DAC half-life creates continuous elevation that may stress joints, particularly in high-dose users.

Can you switch between CJC-1295 with DAC and without DAC during a cycle?

Switching between variants mid-cycle is not recommended because they have different pharmacokinetics—DAC provides sustained elevation while non-DAC creates pulsatile release. Combining them risks excessive GH levels and unpredictable effects. Choose one variant at the start and maintain consistency throughout your cycle.